Adverse drug reactions of Rituximab in patients suffering from autoimmune neurological diseases
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Adverse drug reactions of Rituximab in patients suffering from autoimmune neurological diseases
Authors
Keywords
-
Journal
DARU-Journal of Pharmaceutical Sciences
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2022-09-24
DOI
10.1007/s40199-022-00452-w
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Efficacy and safety of rituximab in myasthenia gravis: a French multicentre real‐life study
- (2020) A. Dos Santos et al. EUROPEAN JOURNAL OF NEUROLOGY
- Managing Risks with Immune Therapies in Multiple Sclerosis
- (2019) Moritz Förster et al. DRUG SAFETY
- Long-term tolerability, safety and efficacy of rituximab in neuromyelitis optica spectrum disorder: a prospective study
- (2019) V. Shaygannejad et al. JOURNAL OF NEUROLOGY
- Efficacy and safety of rituximab for relapsing-remitting multiple sclerosis: A systematic review and meta-analysis
- (2019) Yang Hu et al. AUTOIMMUNITY REVIEWS
- Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies
- (2019) Gustavo Luna et al. JAMA Neurology
- Evaluating the efficacy and safety of ZytuxTM (Rituximab, AryoGen pharmed) in Iranian multiple sclerosis patients: An observational study
- (2019) Abdorreza Naser Moghadasi et al. Multiple Sclerosis and Related Disorders
- Efficacy and safety of rituximab in relapsing and progressive multiple sclerosis: a hospital-based study
- (2018) Carmen Alcalá et al. JOURNAL OF NEUROLOGY
- Effectiveness and safety of Rituximab in multiple sclerosis: an observational study from Southern Switzerland
- (2018) Barbara Scotti et al. PLoS One
- Comparative Effectiveness of Rituximab and Other Initial Treatment Choices for Multiple Sclerosis
- (2018) Mathias Granqvist et al. JAMA Neurology
- Incidence of Infectious Disease and Malignancies After Rituximab Therapy in Kidney Transplant Recipients: Results From a Cohort in Germany
- (2017) E. Schrezenmeier et al. TRANSPLANTATION PROCEEDINGS
- Factors affecting the development of adverse drug reactions to β-blockers in hospitalized cardiac patient population
- (2016) Zoran Todorović et al. Patient Preference and Adherence
- Efficacy and Safety of Rituximab Therapy in Neuromyelitis Optica Spectrum Disorders
- (2016) Valentina Damato et al. JAMA Neurology
- Assessment of a New Instrument for Detecting Preventable Adverse Drug Reactions
- (2014) Raja Benkirane et al. DRUG SAFETY
- Rituximab for induction and maintenance therapy in granulomatosis with polyangiitis (Wegener's). Results of a single-center cohort study on 66 patients
- (2014) Ana Luisa Calich et al. JOURNAL OF AUTOIMMUNITY
- Rituximab in patients with rheumatoid arthritis in routine practice (GERINIS): six-year results from a prospective, multicentre, non-interventional study in 2,484 patients
- (2014) Joerg Wendler et al. ARTHRITIS RESEARCH & THERAPY
- Monoclonal antibody therapy-associated neurological disorders
- (2011) Xavier Bosch et al. Nature Reviews Neurology
- Rituximab infusion-related adverse event rates are lower in patients with systemic lupus erythematosus than in those with rheumatoid arthritis
- (2011) F. Conti et al. RHEUMATOLOGY
- Adverse drug reactions to biologics
- (2010) Kathrin Scherer et al. JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT
- B-cell depletion with rituximab in relapsing-remitting multiple sclerosis
- (2008) Dennis Bourdette et al. Current Neurology and Neuroscience Reports
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More